This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-1751v1 69/3/1063    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Wang, H. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Wang, H.

Proteasome-Mediated Degradation and Functions of Hematopoietic Progenitor Kinase 1 in Pancreatic Cancer

Departments of ¹ Gastrointestinal Medical Oncology, ² Pathology, ³ Cancer Biology, and ⁴ Surgical Oncology, The University of Texas M. D. Anderson Cancer; and Departments of ⁵ Surgery and ⁶ Immunology, Baylor College of Medicine, Houston, Texas

Requests for reprints: Huamin Wang, Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Unit 085, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-563-1846; Fax: 713-563-1848; E-mail: hmwang{at}mdanderson.org.

Key Words: HPK1 • pancreatic adenocarcinoma • proteasome inhibitor • p21 • p27

Hematopoietic progenitor kinase 1 (HPK1) regulates stress responses, proliferation, and apoptosis in hematopoietic cells. In this study, we examined the expression, regulation, and functions of HPK1 in pancreatic ductal adenocarcinomas (PDA). We found that loss of HPK1 protein expression correlated significantly with the progression of pancreatic intraepithelial neoplasias (P = 0.001) and development of invasive PDA. Similarly, HPK1 protein was not expressed in any of eight PDA cell lines examined but was expressed in immortalized human pancreatic duct epithelial (HPDE) cells. There was no difference in HPK1 mRNA levels in PDA cell lines or primary PDA compared with those in HPDE cells or ductal epithelium in chronic pancreatitis and normal pancreas, respectively. Treatment of Panc-1 cells with a proteasome inhibitor, MG132, increased the HPK1 protein levels in a dose-dependent manner, suggesting that alteration in proteasome activity contributes to the loss of HPK1 protein expression in pancreatic cancer. Like the endogenous HPK1, both wild-type HPK1 and its kinase-dead mutant, HPK1-M46, overexpressed in Panc-1 cells, were also targeted by proteasome-mediated degradation. After MG132 withdrawal, wild-type HPK1 protein expression was markedly decreased within 24 hours, but kinase-dead HPK1 mutant protein expression was sustained for up to 96 hours. Therefore, HPK1 kinase activities were required for the loss of HPK1 protein in PDAs. Furthermore, restoring wild-type HPK1 protein in PDA cells led to the increase in p21 and p27 protein expression and cell cycle arrest. Thus, HPK1 may function as a novel tumor suppressor and its loss plays a critical role in pancreatic cancer. [Cancer Res 2009;69(3):1063–70]